5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This cohort study identifies the prevalence of tobacco use and examines the association of both smoking and smoking cessation with survival in a cohort of adults who experienced a myocardial infarction at a young age.

          Key Points

          Question

          Is smoking cessation associated with lower mortality among young adults after an initial myocardial infarction (MI)?

          Findings

          In this cohort study of 2072 individuals who experienced an initial MI at 50 years or younger, approximately half were smokers at the time of their MI, and 62% continued to smoke at 1 year after MI. Smoking cessation within 1 year after MI was associated with a statistically significant reduction in long-term all-cause and cardiovascular mortality.

          Meaning

          Smoking cessation after MI was associated with a clinically significant reduction in all-cause and cardiovascular mortality in a cohort of patients who experienced an MI at a young age.

          Abstract

          Importance

          Despite significant progress in primary prevention, the rate of myocardial infarction (MI) continues to increase in young adults.

          Objectives

          To identify the prevalence of tobacco use and to examine the association of both smoking and smoking cessation with survival in a cohort of adults who experienced an initial MI at a young age.

          Design, Setting, and Participants

          The Partners YOUNG-MI registry is a retrospective cohort study from 2 large academic centers in Boston, Massachusetts, that includes patients who experienced an initial MI at 50 years or younger. Smoking status at the time of presentation and at 1 year after MI was determined from electronic medical records. Participants were 2072 individuals who experienced an MI at 50 years or younger between January 2000 and April 2016. The dates of analysis were October to December 2019.

          Main Outcomes and Measures

          Deaths were ascertained from the Social Security Administration Death Master File, the Massachusetts Department of Vital Statistics, and the National Death Index. Cause of death was adjudicated independently by 2 cardiologists. Propensity score–adjusted Cox proportional hazards modeling was used to evaluate the association between smoking cessation and both all-cause and cardiovascular mortality.

          Results

          Among the 2072 individuals (median age, 45 years [interquartile range, 42-48 years]; 1669 [80.6%] men), 1088 (52.5%) were smokers at the time of their index hospitalization. Of these, 910 patients were further classified into either the cessation group (343 [37.7%]) or the persistent smoking group (567 [62.3%]) at 1 year after MI. Over a median follow-up of 11.2 years (interquartile range, 7.3-14.2 years), individuals who quit smoking had a statistically significantly lower rate of all-cause mortality (hazard ratio [HR], 0.35; 95% CI, 0.19-0.63; P < .001) and cardiovascular mortality (HR, 0.29; 95% CI, 0.11-0.79; P = .02). These values remained statistically significant after propensity score adjustment (HR, 0.30 [95% CI, 0.16-0.56; P < .001] for all-cause mortality and 0.19 [95% CI, 0.06-0.56; P = .003] for cardiovascular mortality).

          Conclusions and Relevance

          In this cohort study, approximately half of individuals who experienced an MI at 50 years or younger were active smokers. Among them, smoking cessation within 1 year after MI was associated with more than 50% lower all-cause and cardiovascular mortality.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review.

          As more interventions become available for the treatment of coronary heart disease (CHD), policy makers and health practitioners need to understand the benefits of each intervention, to better determine where to focus resources. This is particularly true when a patient with CHD quits smoking. To conduct a systematic review to determine the magnitude of risk reduction achieved by smoking cessation in patients with CHD. Nine electronic databases were searched from start of database to April 2003, supplemented by cross-checking references, contact with experts, and with large international cohort studies (identified by the Prospective Studies Collaboration). Prospective cohort studies of patients who were diagnosed with CHD were included if they reported all-cause mortality and had at least 2 years of follow-up. Smoking status had to be measured after CHD diagnosis to ascertain quitting. Two reviewers independently assessed studies to determine eligibility, quality assessment of studies, and results, and independently carried out data extraction using a prepiloted, standardized form. From the literature search, 665 publications were screened and 20 studies were included. Results showed a 36% reduction in crude relative risk (RR) of mortality for patients with CHD who quit compared with those who continued smoking (RR, 0.64; 95% confidence interval [CI], 0.58-0.71). Results from individual studies did not vary greatly despite many differences in patient characteristics, such as age, sex, type of CHD, and the years in which studies took place. Adjusted risk estimates did not differ substantially from crude estimates. Many studies did not adequately address quality issues, such as control of confounding, and misclassification of smoking status. However, restriction to 6 higher-quality studies had little effect on the estimate (RR, 0.71; 95% CI, 0.65-0.77). Few studies included large numbers of elderly persons, women, ethnic minorities, or patients from developing countries. Quitting smoking is associated with a substantial reduction in risk of all-cause mortality among patients with CHD. This risk reduction appears to be consistent regardless of age, sex, index cardiac event, country, and year of study commencement.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes.

            Although preventive drug therapy is a priority after acute coronary syndrome, less is known about adherence to behavioral recommendations. The aim of this study was to examine the influence of adherence to behavioral recommendations in the short term on risk of cardiovascular events. The study population included 18 809 patients from 41 countries enrolled in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS) 5 randomized clinical trial. At the 30-day follow-up, patients reported adherence to diet, physical activity, and smoking cessation. Cardiovascular events (myocardial infarction, stroke, cardiovascular death) and all-cause mortality were documented to 6 months. About one third of smokers persisted in smoking. Adherence to neither diet nor exercise recommendations was reported by 28.5%, adherence to either diet or exercise by 41.6%, and adherence to both by 29.9%. In contrast, 96.1% of subjects reported antiplatelet use, 78.9% reported statin use, and 72.4% reported angiotensin-converting enzyme/angiotensin receptor blocker use. Quitting smoking was associated with a decreased risk of myocardial infarction compared with persistent smoking (odds ratio, 0.57; 95% confidence interval, 0.36 to 0.89). Diet and exercise adherence was associated with a decreased risk of myocardial infarction compared with nonadherence (odds ratio, 0.52; 95% confidence interval, 0.4 to 0.69). Patients who reported persistent smoking and nonadherence to diet and exercise had a 3.8-fold (95% confidence interval, 2.5 to 5.9) increased risk of myocardial infarction/stroke/death compared with never smokers who modified diet and exercise. Adherence to behavioral advice (diet, exercise, and smoking cessation) after acute coronary syndrome was associated with a substantially lower risk of recurrent cardiovascular events. These findings suggest that behavioral modification should be given priority similar to other preventive medications immediately after acute coronary syndrome. Clinical Trial Registration Information- URL: http://clinicaltrials.gov/ct2/show/NCT00139815. Unique identifier: NCT00139815.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                8 July 2020
                July 2020
                8 July 2020
                : 3
                : 7
                : e209649
                Affiliations
                [1 ]Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
                [2 ]Division of Cardiology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
                [3 ]New York Presbyterian/Columbia University Irving Medical Center, New York, New York
                [4 ]Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
                [5 ]Department of Medicine, Tufts Medical Center, Boston, Massachusetts
                [6 ]The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland
                [7 ]Center for Outcomes Research, Houston Methodist, Houston, Texas
                Author notes
                Article Information
                Accepted for Publication: April 20, 2020.
                Published: July 8, 2020. doi:10.1001/jamanetworkopen.2020.9649
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Biery DW et al. JAMA Network Open.
                Corresponding Author: Ron Blankstein, MD, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 ( rblankstein@ 123456bwh.harvard.edu ).
                Author Contributions: Mr Biery and Dr Blankstein had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Biery, Singh, Collins, Gupta, Fatima, Qamar, Blaha, Nasir, Bhatt, Blankstein.
                Acquisition, analysis, or interpretation of data: Biery, Berman, Singh, Divakaran, DeFilippis, Collins, Gupta, Fatima, Qamar, Klein, Hainer, Di Carli, Bhatt, Blankstein.
                Drafting of the manuscript: Biery, Berman, Divakaran, DeFilippis, Collins, Fatima, Blankstein.
                Critical revision of the manuscript for important intellectual content: Biery, Berman, Singh, Divakaran, DeFilippis, Gupta, Fatima, Qamar, Klein, Hainer, Blaha, Di Carli, Nasir, Bhatt, Blankstein.
                Statistical analysis: Biery, Singh, Gupta, Fatima, Qamar.
                Administrative, technical, or material support: Berman, Divakaran, Klein, Hainer, Blaha, Blankstein.
                Supervision: Fatima, Blaha, Nasir, Bhatt, Blankstein.
                Conflict of Interest Disclosures: Dr Berman reported being supported by a T32 postdoctoral training grant from the National Heart, Lung, and Blood Institute (NHLBI). Dr Divakaran reported receiving grants from the NHLBI. Dr Gupta reported receiving grants from the National Institutes of Health (NIH) and an honorarium from Abiomed. Dr Blaha reported receiving grants from the Aetna Foundation, American Heart Association, NIH, and US Food and Drug Administration; receiving grants and personal fees from Amgen Foundation; and receiving personal fees from Akcea, Bayer, Novartis, Novo Nordisk, Regeneron, and Sanofi. Dr Di Carli reported receiving grants from Gilead Sciences and Spectrum Dynamics and receiving personal fees from Bayer and Janssen. Dr Nasir reported serving on advisory boards for Amgen, Esperion, and Novartis and receiving support from the Katz Academy of Translational Research. Dr Bhatt reported receiving grants from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bristol-Myers, Cardax, Chiesi, Eisai, Ethicon, Forest Laboratories/AstraZeneca, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi-Aventis, Squibb, Synaptic, and The Medicines Company; receiving personal fees from the American College of Cardiology, Bayer, Belvoir Publications, Boehringer Ingelheim, Cleveland Clinic, CSL Behring, Duke Clinical Research Institute, Elsevier, Ferring Pharmaceuticals, Harvard Clinical Research Institute (now Baim Institute for Clinical Research), HMP Global, Journal of the American College of Cardiology, Mayo Clinic, Medtelligence/ReachMD, MJH Life Sciences, Mount Sinai School of Medicine, Population Health Research Institute, Slack Publications, Society of Cardiovascular Patient Care, TobeSoft, and WebMD; and receiving nonfinancial support from the American Heart Association, Biotronik, Boston Scientific, Boston VA Research Institute, Cereno Scientific, Clinical Cardiology, CSI, Flowco, Medscape Cardiology, Merck, Novo Nordisk, Regado Biosciences, St Jude Medical (now Abbott), Svelte, Takeda, and US Department of Veterans Affairs. Dr Blankstein reported receiving research support from Amgen Inc and Astellas Inc. No other disclosures were reported.
                Funding/Support: Drs Berman and Divakaran are supported by a T32 postdoctoral training grant from the NHLBI (T32 HL094301). Dr Qamar is supported by a T32 postdoctoral training grant from the NHLBI (T32 HL007604).
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: Arlene S. Ash, PhD, and Jonggyu Baek, PhD, of the University of Massachusetts Medical School collaborated in calculating the neighborhood stress score for the patients in this study. Camden Bay, PhD, of Brigham and Women’s Hospital provided advice and assistance regarding the statistical methods. They were not compensated for their contributions.
                Article
                zoi200400
                10.1001/jamanetworkopen.2020.9649
                7344383
                32639567
                dbd4eb2d-90a0-45b6-80f0-4863e99b77e7
                Copyright 2020 Biery DW et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 2 February 2020
                : 20 April 2020
                Categories
                Research
                Original Investigation
                Featured
                Online Only
                Cardiology

                Comments

                Comment on this article